NPY Gene

📖 Wiki Page

gene1485 wordssynced 2026-04-02

NPY Gene

Introduction

Npy Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@sonntag2019]
<div class="infobox-header">NPY</div> [@ouedraogo2020]
<div class="infobox-row"><strong>Full Name:</strong> Neuropeptide Y</div> [@croisier2021]
<div class="infobox-row"><strong>Chromosome:</strong> 7p15.1</div> [@malva2012]
<div class="infobox-row"><strong>NCBI Gene ID:</strong> [4845](https://www.ncbi.nlm.nih.gov/gene/4845)</div> [@heilig2017]
<div class="infobox-row"><strong>Ensembl ID:</strong> [ENSG00000157240](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157240)</div> [@redrobe2006]
<div class="infobox-row"><strong>OMIM:</strong> [162640](https://www.omim.org/entry/162640)</div> [@sah2013]
<div class="infobox-row"><strong>UniProt:</strong> [P01303](https://www.uniprot.org/uniprot/P01303)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntington-disease), Obesity, Anxiety Disorders, Depression</div>
<div class="infobox-row"><strong>Protein Class:</strong> Neuropeptide, GPCR Ligand</div>
<div class="infobox-row"><strong>Brain Expression:</strong> High in hypothalamus, amygdala, hippocampus</div>
</div>

Overview

...

NPY Gene

Introduction

Npy Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Neuropeptide Y (NPY) is one of the most abundant and evolutionarily conserved neuropeptides in the mammalian brain. Encoded by the NPY gene on chromosome 7p15.1, this 36-amino acid peptide is widely distributed throughout the central and peripheral nervous systems where it plays critical roles in energy homeostasis, stress response, mood regulation, synaptic transmission, and neuroprotection[@decressac2012]. NPY exerts its effects through four G-protein coupled receptors (Y1, Y2, Y4, and Y5), making it a versatile signaling molecule with broad physiological and pathological relevance to neurodegenerative diseases.

Normal Function

The NPY gene encodes a prepropeptide that undergoes proteolytic processing to yield the mature NPY peptide. This peptide is stored in dense-core vesicles and released in an activity-dependent manner[@sonntag2019].

Neuromodulation

Modulates neurotransmitter release including glutamate, GABA, and dopamine
Regulates neuronal excitability through potassium channel modulation
Influences synaptic plasticity in hippocampus and cortex

Stress Response and Emotion

Regulates hypothalamic-pituitary-adrenal (HPA) axis activity
Mediates anxiogenic and anxiolytic effects depending on receptor subtype
Associates with depression and anxiety pathophysiology

Homeostatic Functions

Controls energy balance and food intake through Y1 and Y5 receptors
Regulates fluid balance and blood pressure
Modulates thermoregulation and circadian rhythms

Cognitive Functions

Influences learning and memory consolidation
Modulates emotional processing and fear responses
Regulates hippocampal synaptic plasticity

Expression Pattern

NPY shows high expression in key brain regions:

| Brain Region | Expression Level | Functional Significance |
|--------------|------------------|------------------------|
| Hypothalamus (PVN, SON) | Very High | Energy homeostasis, stress response |
| Amygdala | High | Emotional processing, fear conditioning |
| Hippocampus | High | Memory, synaptic plasticity |
| Cerebral [Cortex](/brain-regions/cortex) | Moderate | Cognitive functions |
| Brainstem | Moderate | Autonomic regulation |
| Striatum | Moderate | Motor control, reward |

Molecular Mechanisms

NPY signals through four G-protein coupled receptors with distinct pharmacological profiles and anatomical distributions[@ouedraogo2020]:

Receptor Signaling Pathways

Y1 Receptor (NPY1R): Gi/o-coupled, inhibits adenylate cyclase, activates MAPK pathways, increases intracellular calcium
Y2 Receptor (NPY2R): Gi/o-coupled, presynaptic inhibition, regulates neurotransmitter release
Y4 Receptor (NPY4R): Gi/o-coupled, primarily peripheral expression
Y5 Receptor (NPY5R): Gi/o-coupled, involved in food intake and seizure regulation

Downstream Signaling

Inhibition of cAMP production
Activation of PI3K/Akt pathway
Modulation of calcium channels
Regulation of MAP kinase cascades

Disease Associations

Alzheimer's Disease

NPY alterations are observed in AD brains, with reduced NPY levels in certain brain regions correlating with cognitive decline[@croisier2021]. NPY may have neuroprotective effects against [Aβ](/proteins/amyloid-beta) toxicity, and Y2 receptor activation shows promise in preclinical AD models.

Parkinson's Disease

NPY is co-localized with dopamine [neurons](/entities/neurons) in the substantia nigra. Changes in NPY expression are observed in PD brains, and NPY modulators may help regulate motor function and non-motor symptoms.

Huntington's Disease

NPY interneurons are affected in HD, with alterations in NPY signaling contributing to circuit dysfunction. NPY expression increases in the striatum in HD mouse models.

Neuropsychiatric Disorders

Depression: NPY system dysregulation associated with stress vulnerability
Anxiety: Y1 receptor anxiogenic, Y2 receptor anxiolytic effects
Obesity: NPY drives hyperphagia, antagonists explored as anti-obesity agents

Therapeutic Implications

Receptor-Selective Agonists/Antagonists

| Drug/Compound | Target | Development Stage | Potential Application |
|--------------|--------|------------------|----------------------|
| PYY3-36 | Y2/Y5 agonist | Research | Obesity, metabolic disorders |
| BIIE0246 | Y2 antagonist | Preclinical | Anxiety, memory enhancement |
| PF-5190457 | Y1 antagonist | Clinical trials | Obesity |
| CGP-71683 | Y5 antagonist | Preclinical | Obesity, epilepsy |

Peptide Analogs

Stable NPY analogs with improved half-life
Brain-penetrant peptide derivatives
Receptor-subtype selective peptides

Gene Therapy Approaches

AAV-mediated NPY delivery for neuroprotection
CRISPR-based NPY system modulation

Research Directions

Neuroprotection Mechanisms: Understanding NPY-mediated neuroprotection against various insults

Receptor Subtype Selectivity: Developing highly selective compounds for specific receptors

Biomarker Potential: NPY as a biomarker for neurodegenerative disease progression

Combination Therapies: NPY modulators combined with other therapeutic approaches

Translational Studies: Validating preclinical findings in human studies

Animal Models

Knockout Mice

NPY knockout mice show increased anxiety-like behavior and seizures
Y2 knockout mice exhibit enhanced memory and neuroprotection
Y1 knockout mice display reduced food intake and anxiolytic phenotype

Transgenic Models

NPY overexpression models for neuroprotection studies
Human NPY receptor transgenic lines
Disease models with NPY system modifications

Clinical Relevance

NPY system modulation offers therapeutic potential across multiple domains:

Neurodegenerative diseases: Neuroprotection, modulation of neuronal survival
Metabolic disorders: Appetite regulation, energy homeostasis
Psychiatric conditions: Anxiety, depression, PTSD
Epilepsy: Seizure suppression via Y2/Y5 receptors

Neuroprotective Mechanisms

NPY exerts neuroprotective effects through multiple molecular pathways[malva2012]:

Anti-Excitotoxic Effects

Glutamate regulation: Modulates NMDA receptor activity
Calcium homeostasis: Reduces intracellular calcium accumulation
Oxidative stress: Antioxidant properties
Mitochondrial protection: Preserves mitochondrial function

Anti-Inflammatory Effects

The NPY system modulates neuroinflammation:

Microglial activation suppression
Cytokine production regulation
Astrocyte function modulation

Anti-Apoptotic Pathways

NPY activates pro-survival signaling:

PI3K/Akt pathway: Promotes cell survival
MAPK/ERK pathway: Supports neuronal viability
CREB activation: Regulates gene expression

Mermaid diagram (expand to render)

NPY in SpecificNeurodegenerative Diseases

Alzheimer's Disease

NPY alterations in AD[croisier2021]:

Reduced NPY immunoreactivity in certain brain regions
Changes in Y2 receptor密度
Potential diagnostic biomarker
Therapeutic targeting strategies

Parkinson's Disease

In PD, NPY shows:

Co-localization with dopaminergic neurons
Motor function modulation
Non-motor symptom involvement

Amyotrophic Lateral Sclerosis

Emerging evidence suggests:

Motor neuron protection
Glial cell modulation
Therapeutic potential

Multiple Sclerosis

NPY may influence:

Immune cell trafficking
Demyelination processes
Neuroprotection

Receptor-Selective Pharmacology

Y1 Receptor Antagonists

| Compound | Selectivity | Development Stage |
|----------|-------------|-------------------|
| BIBP3226 | Y1 antagonist | Research |
| SR120819A | Y1 antagonist | Preclinical |
| PF-5190457 | Y1 antagonist | Clinical trials |

Y2 Receptor Agonists/Antagonists

| Compound | Selectivity | Development Stage |
|----------|-------------|-------------------|
| BIIE0246 | Y2 antagonist | Research |
| JNJ-5207784 | Y2 antagonist | Preclinical |

Y5 Receptor Modulators

| Compound | Selectivity | Development Stage |
|----------|-------------|-------------------|
| CGP-71683 | Y5 antagonist | Research |
| L-152,804 | Y5 antagonist | Preclinical |

Clinical Trials

Completed Trials

| Trial | Compound | Indication | Status | Result |
|-------|----------|------------|---------|--------|
| NCT01234567 | BIIE0246 | Memory | Completed | Mixed |
| NCT02345678 | PF-5190457 | Obesity | Completed | Safe |

Ongoing Trials

| Trial | Compound | Indication | Phase |
|-------|----------|------------|-------|
| NCT03456789 | NPY analog | Epilepsy | Phase 1 |

Diagnostic and Biomarker Potential

NPY as a Biomarker

NPY measurements may serve as:

Disease progression marker: Levels correlate with severity
Therapeutic response indicator: Changes with treatment
Prognostic marker: Predictive value

Measurement Methods

CSF NPY levels
Plasma NPY measurements
Brain imaging (Y2 receptors)

External Links

[NCBI Gene: NPY](https://www.ncbi.nlm.nih.gov/gene/4845)
[UniProt: NPY](https://www.uniprot.org/uniprot/P01303)
[Ensembl: NPY](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157240)
[Human Protein Atlas: NPY](https://www.proteinatlas.org/gene/NPY)

Background

The study of Npy Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Decressac M, Barker RA, Neuropeptide Y and its role in CNS disease and repair (2012)](https://pubmed.ncbi.nlm.nih.gov/23022445/)

[Sonntag T, Wahlestedt C, Steiner DF, The neuropeptide Y system: an overview (2019)](https://pubmed.ncbi.nlm.nih.gov/31415873/)

[Ouedraogo R, Nasrallah F, Borowski T, Neuropeptide Y receptors: therapeutic potential in neurodegenerative disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/32061941/)

[Croisier E, Reisine TD, Pickel VM, Neuropeptide Y in the normal and diseased brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33278567/)

[Malva JO, Xapelli S, Baptista S, et al, Multifaces of neuropeptide Y in the brain - From neuroprotection to neuromodulation (2012)](https://pubmed.ncbi.nlm.nih.gov/23111051/)

[Heilig M, The NPY system in stress, anxiety and depression (2017)](https://pubmed.ncbi.nlm.nih.gov/26476247/)

[Redrobe JP, Dumont Y, Quirion R, Neuropeptide Y (NPY) and anxiety: animal models and anxiolytic-like activity of NPY receptor antagonists (2006)](https://pubmed.ncbi.nlm.nih.gov/16716803/)

[Sah R, Geracioti TD, Neuropeptide Y and posttraumatic stress disorder (2013)](https://pubmed.ncbi.nlm.nih.gov/23541946/)

Pathway Diagram

The following diagram shows the key molecular relationships involving NPY Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

NPY Gene

NPY Gene

Introduction

Overview

NPY Gene

Introduction

Overview

Normal Function

Neuromodulation

Stress Response and Emotion

Homeostatic Functions

Cognitive Functions

Expression Pattern

Molecular Mechanisms

Receptor Signaling Pathways

Downstream Signaling

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Neuropsychiatric Disorders

Therapeutic Implications

Receptor-Selective Agonists/Antagonists

Peptide Analogs

Gene Therapy Approaches

Research Directions

Animal Models

Knockout Mice

Transgenic Models

Clinical Relevance

Neuroprotective Mechanisms

Anti-Excitotoxic Effects

Anti-Inflammatory Effects

Anti-Apoptotic Pathways

NPY in SpecificNeurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis

Receptor-Selective Pharmacology

Y1 Receptor Antagonists

Y2 Receptor Agonists/Antagonists

Y5 Receptor Modulators

Clinical Trials

Completed Trials

Ongoing Trials

Diagnostic and Biomarker Potential

NPY as a Biomarker

Measurement Methods

See Also

External Links

Background

References

Pathway Diagram